Clinical Trial to Compare Pharmacokinetics After Administration of ATB-101 or Co-administration of ATB-1011 and ATB-1012

• Status: Completed
• Trial end date: 2021-07-12
• Target enrollment: 0
• Participant gender: All

Summary

To compare and evaluate safety and pharmacokinetic Characteristics after administration of ATB-101 or co-administration of ATB-1011 and ATB-1012 in fasted Healthy Adult Volunteers

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Autotelicbio
• Treatments: Olmesartan Medoxomil

Criteria

Inclusion Criteria:

• Those who are over 19 years old at the screening visit

• Those who do not have clinically significant congenital or chronic diseases and have no pathological symptoms or findings upon medical examination at the screening visit

• Those who determined as suitable study subjects by the principal investigator

• A person who signs the consent form at will, after hearing and understanding a sufficient explanation of the purpose, contents, characteristics of the investigational product, and expected adverse reactions of this clinical trial

Exclusion Criteria:

• Those who have a clinically significant disease or have a history of such disease

• Those who have a history of gastrointestinal surgery

• Those who have taken drugs that induce and inhibit metabolism enzymes such as barbital drugs

• Those who participated in other clinical trials or bioequivalence studies and administered the investigational products within 6 months of the first administration date.

• Those who donated whole blood within 2 months or donated components within 2 weeks, or received a blood transfusion within 1 month of the first administration date